Fig. 2: Treatment response. | Nature Communications

Fig. 2: Treatment response.

From: Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial

Fig. 2

Results of pathological regression (a) and radiologic response assessed using the Response Evaluation Criteria in Solid Tumours (version 1.1) (b) in patients eligible for assessments (n = 98 and 103, respectively). CA-SAP camrelizumab, apatinib, nab-paclitaxel, and S-1, SAP nab-paclitaxel and S-1. Source data are provided as a Source data file.

Back to article page